Literature DB >> 33564486

Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach.

Gabriel Fridolin Hess1, Savas Deniz Soysal1, Guillaume Nicolas2, Martin Bolli1, Christoph Johannes Zech2, Alexandar Tzankov3, Emanuel Christ4, Michael Montemurro5, Otto Kollmar1.   

Abstract

BACKGROUND: Neuroendocrine tumors (NETs) are a rare entity and are most commonly found in the gastroenteropancreatic tract. The clinical outcome depends on the potential resectability, grade, and stage. Here, we report a case of a tumor debulking in a metastatic NET of the pancreas. A 25-year-old woman with stable metastatic NET of the pancreas G2 T4N1M1 (hepatic, extrahepatic) already underwent several therapies. Case Presentation. A 25-year-old woman with stable metastatic NET of the pancreas G2 T4N1M1 (hepatic, extrahepatic) already underwent several pharmaceutical therapies. Due to the young age, the G2 characteristic, and the stable liver disease, the decision for debulking was made. Based on a 3D CT scan, an embolization was successfully performed directly prior to a pylorus-preserving pancreatic head resection, advanced interaortocaval lymph node dissection, and an atypical liver resection within segment VI. Histological workup revealed a stage pT3, G2, pN1 (29/34), pM1c (hepatic and extrahepatic), L1, V0, Pn0 with complete surgical resection of the primary tumor (180 mm). The excision of the liver segment V showed a completely resected metastasis.
CONCLUSIONS: In this patient, extensive surgery of a pancreatic NET with the aim of a prolonged progression-free survival was performed. Close cooperation between different disciplines is absolutely mandatory. Modern imaging allowed a precise therapy plan to be worked out.
Copyright © 2021 Gabriel Fridolin Hess et al.

Entities:  

Year:  2021        PMID: 33564486      PMCID: PMC7850824          DOI: 10.1155/2021/8811155

Source DB:  PubMed          Journal:  Case Rep Surg


  13 in total

1.  Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.

Authors:  Jan Franko; Wentao Feng; Linwah Yip; Elizabeth Genovese; A James Moser
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

2.  Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.

Authors:  Stefano Partelli; Emilio Bertani; Mirco Bartolomei; Carolina Perali; Francesca Muffatti; Chiara Maria Grana; Marco Schiavo Lena; Claudio Doglioni; Stefano Crippa; Nicola Fazio; Giuseppe Zamboni; Massimo Falconi
Journal:  Surgery       Date:  2017-12-25       Impact factor: 3.982

3.  Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Authors:  Hong Shen; Zhuo Yu; Jing Zhao; Xiu-Zhen Li; Wen-Sheng Pan
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

4.  Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Authors:  Hiromichi Ito; Michael Abramson; Kaori Ito; Edward Swanson; Nancy Cho; Daniel T Ruan; Richard S Swanson; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2010-03-12       Impact factor: 3.452

5.  First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.

Authors:  Francesco Panzuto; Elettra Merola; Marianne Ellen Pavel; Anja Rinke; Patrizia Kump; Stefano Partelli; Maria Rinzivillo; Victor Rodriguez-Laval; Ulrich Frank Pape; Rainer Lipp; Thomas Gress; Bertram Wiedenmann; Massimo Falconi; Gianfranco Delle Fave
Journal:  Oncologist       Date:  2017-02-23

Review 7.  The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.

Authors:  David S Klimstra; Irvin R Modlin; Domenico Coppola; Ricardo V Lloyd; Saul Suster
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

8.  Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Xavier M Keutgen; Naris Nilubol; Joanne Glanville; Samira M Sadowski; David J Liewehr; David J Venzon; Seth M Steinberg; Electron Kebebew
Journal:  Surgery       Date:  2015-10-06       Impact factor: 3.982

9.  Incidence of Neuroendocrine Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States.

Authors:  Nicolas Patel; Bikramjit Benipal
Journal:  Cureus       Date:  2019-03-26

10.  Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database.

Authors:  Yunghun You; Jin-Young Jang; Song Cheol Kim; Yoo-Seok Yoon; Joon Seong Park; Chol Kyoon Cho; Sang-Jae Park; Jae Do Yang; Woo Jung Lee; Tae Ho Hong; Keun Soo Ahn; Chi-Young Jeong; Hyeon Kook Lee; Seung Eun Lee; Young Hoon Roh; Hee Joon Kim; Hongbeom Kim; In Woong Han
Journal:  Cancer Res Treat       Date:  2019-04-19       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.